SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder

Shire

Status and phase

Completed

Phase 3

Conditions

Binge Eating Disorder

Treatments

Drug: SPD489 (Lisdexamfetamine dimesylate)

Drug: Placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT01718483

2012-003309-91 (EudraCT Number)

SPD489-343

Details and patient eligibility

About

The primary objective of the study is to demonstrate the efficacy of SPD489 compared with placebo in adults (18 55 years of age inclusive) with moderate to severe Binge Eating Disorder at Visit 8 (Weeks 11 and 12) as measured by the number of binge days (defined as days during which at least 1 binge episode occurs) per week as assessed by clinical interview based on subject diary

Enrollment

383 patients

Sex

All

Ages

18 to 55 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria -

Subject is between 18-55 years of age.
Subject meets the following DSM-IV-TR criteria for a diagnosis of BED:

Recurrent episodes of binge eating. An episode of binge eating is characterized by both of the following: eating, in a discrete period of time (eg, within a 2-hour period) an amount of food that is definitely larger than most people would eat in a similar period of time under similar conditions, and a sense of lack of control over the eating (eg, a feeling that one cannot stop eating or control what or how much one is eating).

The binge eating episodes are associated with at least 3 of the following: eating much more rapidly than normal; eating until uncomfortably full; eating large amounts of food when not feeling physically hungry; eating alone because of being embarrassed by how much one is eating; feeling disgusted with oneself, depressed, or feeling very guilty after overeating.

Marked distress regarding binge eating. The binge eating occurs, on average, at least 2 days a week for 6 months. The episodes of binge eating do not occur exclusively during the course of bulimia nervosa or anorexia nervosa.
Subject's BED is of at least moderate severity with subjects reporting at least 3 binge eating days per week for the 14 days prior to the Baseline Visit (Visit 0) as documented in the subject's binge diary. A binge day is a day during which at least 1 binge eating episode occurs.
Female subjects must have a negative serum B HCG pregnancy test and a negative urine pregnancy test.

Exclusion Criteria-

Subject has concurrent symptoms of bulimia nervosa or anorexia nervosa.
Subject is receiving psychotherapy (eg, supportive psychotherapy, cognitive behavior therapy, interpersonal therapy) or weight loss support (eg, Weight Watchers) for BED within 3 months.
Subject has used psychostimulants to facilitate fasting or dieting as a part of their BED within 6 months.
Subject has a lifetime history of psychosis, mania, hypomania, dementia, or ADHD.
Subject is considered a suicide risk in the opinion of the investigator, has previously made a suicide attempt, or is currently demonstrating active suicidal ideation. Subjects with intermittent passive suicidal ideation are not necessarily excluded based on the assessment of the investigator.
Subject has known history of symptomatic cardiovascular disease, advanced arteriosclerosis, structural cardiac abnormality, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems.
Subject has recently initiated treatment with a lipid-lowering medication (within the past 3 months).
Subject has a history of moderate or severe hypertension.
Subject is female and pregnant or nursing.
Subjects who have had bariatric surgery, lap bands, duodenal stents, or other procedures for weight loss.